NeuroPace Inc. Announces Public Offering of Common Stock
NeuroPace, Inc. (NASDAQ: NPCE) has officially announced the pricing of its public offering involving 6,500,000 shares of common stock at $10.00 per share. This step highlights the company's commitment to expanding its reach and improving patient care, particularly for those suffering from epilepsy. The total expected gross proceeds from this offering are projected to be around $65 million prior to underwriting discounts and commissions as well as other offering expenses.
Utilization of Proceeds
The company intends to channel approximately $49.5 million of the net proceeds toward repurchasing shares from one of its significant stockholders, KCK Ltd., at a price of $9.40 each. This repurchase will be executed at the same price the underwriters will pay to acquire shares directly from NeuroPace. Furthermore, the remaining proceeds from the offering, along with any additional funds from the exercise of the underwriters' option, will be allocated for various corporate purposes. These may include expenses related to clinical trials and research and development, as well as administrative expenses, debt reduction, and working capital.
Details on the Offering Process
The offering is a product of a shelf registration statement that NeuroPace filed with the Securities and Exchange Commission (SEC), which took effect on a specific date. This means that the shares offered by NeuroPace are compliant with SEC regulations, ensuring transparency and legality in the sale process. Investors can access the preliminary prospectus and accompanying documentation on the SEC's website for further details. A final prospectus will also be provided once it is completed.
About NeuroPace
NeuroPace is a cutting-edge medical device company dedicated to improving the lives of individuals living with epilepsy. The company specializes in the innovative RNS System, which stands as the first commercially available platform capable of delivering personalized therapies in real-time at the site of seizures. This forward-thinking technology is poised to enhance the standard of care for patients enduring drug-resistant epilepsy, also holding the potential to positively affect other brain disorders.
Management Team and Future Prospects
The offering is structured with the involvement of several notable firms, including J.P. Morgan, Cantor Fitzgerald, Wells Fargo Securities, and Leerink Partners. These companies are facilitating the offering process, showcasing the confidence in NeuroPace's forward momentum. Looking ahead, NeuroPace aims to utilize these funds strategically to bolster its initiatives for advancing medical solutions that can lead to enhanced patient outcomes.
Frequently Asked Questions
What is the purpose of NeuroPace's public offering?
The public offering aims to raise funds that will help NeuroPace repurchase shares and support ongoing research and development initiatives.
How does NeuroPace's RNS System work?
The RNS System is a brain-responsive technology that delivers personalized, real-time treatment to individuals experiencing seizures.
Who are the key players managing the offering?
The offering process is managed by firms including J.P. Morgan, Cantor Fitzgerald, Wells Fargo Securities, and Leerink Partners.
What is the expected gross revenue from the offering?
The projected gross revenue from the offering is $65 million before deductions for underwriting fees and expenses.
How will the proceeds be used?
The proceeds will primarily be used for share repurchases, general corporate purposes, and research and development activities.
